Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.
Publication Title
Ther Adv Musculoskelet Dis
Document Type
Article
Publication Date
1-1-2022
Keywords
washington; swedish; certolizumab pegol; disease control; psoriatic arthritis; treatment targets; work productivity
Abstract
BACKGROUND: Psoriatic arthritis (PsA) impacts the physical health and functional ability of patients, leading to reduced productivity. High unemployment rates and absence due to sickness have been reported in patients with PsA.
OBJECTIVES: This
DESIGN: RAPID-PsA was a 216-week phase III trial.
METHODS: This
RESULTS: In all, 273 patients were randomised to certolizumab pegol and 183 (67.0%) completed Week 216. At baseline, 60.8% of patients were employed outside the home. Improved disease control, measured using ACR and DAPSA criteria, was associated with fewer cumulative days affected by workplace absenteeism through Week 216: ACR70: 4.1 days, ACR50 to <70: >7.7, ACR20 to <50: >20.9,
CONCLUSION: This
Clinical Institute
Orthopedics & Sports Medicine
Specialty/Research Institute
Rheumatology
Specialty/Research Institute
Orthopedics
